RBC Capital Maintains Outperform on Medline, Lowers Price Target to $46
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Ryan Halsted maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $53 to $46.
RBC Capital analyst Ryan Halsted maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $53 to $46.